| Type 2 Diabetes Mellitus |
1 |
1 |
| Cancer |
0 |
0.63 |
| Obesity |
0 |
0.6 |
| Brain Cancer |
0 |
0.46 |
| Head and Neck Cancer |
0 |
0.46 |
| Lung Cancer |
0 |
0.46 |
| Liver Disease |
0 |
0.45 |
| Toxicology |
0 |
0.45 |
| Liver |
0 |
0.24 |
| Prediabetes |
0 |
0.24 |
| Peripheral Artery Disease |
0 |
0.22 |
| Thoracic Surgery |
0 |
0.22 |
| Atherosclerosis |
0 |
0.19 |
| Cognitive Impairment |
0 |
0.17 |
| Coronary Artery Disease (CAD) |
0 |
0.17 |
| Artery |
0 |
0.16 |
| Blood |
0 |
0.16 |
| Europe |
0 |
0.16 |
| Impairment |
0 |
0.16 |
| Lung |
0 |
0.16 |
| New York |
0 |
0.16 |
| Surgery |
0 |
0.16 |
| Tumor |
0 |
0.16 |
| Skeletal Myoblasts |
0 |
0.15 |
| Alzheimer Disease |
0 |
0.14 |
| Renal Disease |
0 |
0.14 |
| Mild Cognitive Impairment |
0 |
0.12 |
| Catheter Ablation |
0 |
0.11 |
| Lactic Acidosis |
0 |
0.11 |
| Polycystic Ovary Syndrome |
0 |
0.11 |
| Vitamin B12 Deficiency |
0 |
0.11 |
| Ablation |
0 |
0.08 |
| Acidosis |
0 |
0.08 |
| Adverse Effects |
0 |
0.08 |
| Antipsychotics |
0 |
0.08 |
| Antiviral Agents |
0 |
0.08 |
| Board Certification |
0 |
0.08 |
| Brain |
0 |
0.08 |
| Canada |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Colorado |
0 |
0.08 |
| Endocrinology |
0 |
0.08 |
| Geriatrics |
0 |
0.08 |
| Gestational Diabetes Mellitus |
0 |
0.08 |
| Infarction |
0 |
0.08 |
| Kidney |
0 |
0.08 |
| Metabolism |
0 |
0.08 |
| Muscle |
0 |
0.08 |
| Off-Label Use |
0 |
0.08 |
| Ovary |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| Skeletal |
0 |
0.08 |
| Vitamin |
0 |
0.08 |
| Weight Gain |
0 |
0.08 |
| Atrial Fibrillation |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Infertility Female |
0 |
0.07 |
| Lipids Management |
0 |
0.07 |
| Patient Safety |
0 |
0.07 |
| Pregnancy |
0 |
0.07 |
| Weight Management |
0 |
0.07 |